The INOpulse portable oxygen provider widened blood vessels, lowered blood pressure and increased exercise capacity in pulmonary hypertension patients with idiopathic pulmonary fibrosis (PH-IPF), according to a study. Bellerophon Therapeutics, which ... Read more
Bellerophon Therapeutics recently offered an update on the company’s INOpulse system, as part of its first quarter 2017 financial report. The system is in clinical testing as a therapy for three types of pulmonary hypertension. The ... Read more
Third Pole has won a Johnson & Johnson Innovation award for a lighter device that provides an unlimited supply of nitric oxide (NO) to patients with pulmonary hypertension (PH) and other respiratory conditions. ... Read more
The INOpulse nitric-oxide dispenser improves respiratory and exercise capacity in patients with difficult-to-treat pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF), a Phase 2 trial indicates. Bellerophon Therapeutics, which developed INOpulse, will present ... Read more
In this animated video from Gopal Sikder, viewers learn about the pathophysiology of pulmonary arterial hypertension (PAH). MORE: Revatio as inhaled PAH treatment is more effective than tablets now available a study ... Read more
Nitric oxide inhalation can significantly improve oxygen supply in newborn babies with pulmonary hypertension according to a study published in the journal European Review for Medical and Pharmacological Sciences.
Inhalation treatment that uses either nitric oxide or Ventavis (iloprost) is equally effective in managing lingering high lung blood pressure after surgery for chronic thromboembolic pulmonary hypertension (CTEPH). A comparison of the two ... Read more
The use of nitrite salts for the treatment of cardiovascular conditions, such as pulmonary hypertension, is now patented by the U.S. Patent and Trademark Office (USPTO). The new patent (US ... Read more